Intellia Therapeutics, Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • ADMET
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule

Other Names/Subsidiaries

  • Caribou Biosciences
  • eXtellia Therapeutics
  • Rewrite Therapeutics
See more in Biomedtracker

Latest on Intellia Therapeutics, Inc.

Scrip

Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets

 
• By Mandy Jackson

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

Scrip

Stock Watch: J&J, GSK, Lilly Bring J.P. Morgan Cheer

 
• By Andy Smith

January’s J.P. Morgan Healthcare Conference should set the tempo for biotech and pharma companies over the year as mergers and acquisitions along with early announcements of full-year 2024 financials

Scrip

Intellia Moves Into Phase III With NTLA-2002, But Concerns Remain

 
• By Alaric DeArment

Intellia Therapeutics, Inc.’s NTLA-2002 holds a strong position as it heads into Phase III development for hereditary angioedema (HAE), with Phase II data showing a high rate of functional cure. Howev

Scrip

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

 
• By Mandy Jackson

The latest third quarter data from the National Venture Capital Association (NVCA) and Pitchbook’s Venture Monitor report confirm recent data compiled by Evaluate Pharma, which showed that VC investme